Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Author:

Siefker-Radtke A.O.,Matsubara N.,Park S.H.,Huddart R.A.,Burgess E.F.,Özgüroğlu M.ORCID,Valderrama B.P.,Laguerre B.,Basso U.,Triantos S.,Akapame S.,Kean Y.,Deprince K.,Mukhopadhyay S.,Loriot Y.,Bastick Patricia,Sewak Sanjeev,Tran Ben,Pichler Martin,Shariat Shahrokh,Rottey Sylvie,Schatteman Peter,Schrijvers Dirk,Verschaeve Vincent,Vulsteke Christof,Barros Leite Ferreira Luiza Aleixo,de Santana Gomes Andrea Juliana Pereira,Junior Joao Antonio,Azevedo Sergio,Bastos Diogo,Borges Giuliano,Dettino Aldo,Antonio Pires Luis,Luz Murilo,Martins Suelen,Mota Jose Mauricio,Toledo Joseane,Eigl Bernhard,Finch Daygen,Gingerich Joel,Dong Haiying,Huang Jian,Jin Jie,Pan Hongming,Sun Zhongquan,Tian Ye,Wan Ben,Wu Bin,Xu Ting,Xue Wei,Zhou Fangjian,Barthelemy Philippe,Borchiellini Delphine,Calcagno Fabien,Carnot Aurelien,Cornillon Pierre,Delva Remy,Emambux Sheik,Houede Nadine,Laguerre Brigitte,Lauridant Géraldine,Loriot Yohann,Mahammedi Hakim,Maillet Denis,Pouessel Damien,Roubaud Guilhem,Schlurmann-Constans Friederike,Tosi Diego,Zanetta Sylvie,Banek Severine,Feyerabend Susan,Kramer Mario,Niegisch Guenther,Nuhn Philipp,Schnabel Marco,Wuelfing Christian,Baka Sofia,Bamias Aristotelis,Fountzilas George,Kalofonos Harabolos,Karalis Konstantinos,Kotsakis Athanasios,Timotheadou Eleni,Landherr Laszlo,Mangel Laszlo,Pe’er Avivit,Levratovsky Meital,Basso Umberto,Battelli Nicola,Cavo Alessia,De Giorgi Ugo,Doni Laura,Galli Luca,Gigante Maria Olga,Guadalupi Valentina,Maio Michele,Milesi Laura,Nolè Franco,Scagliotti Giorgio,Tortora Giampaolo,Fukasawa Satoshi,Harabayashi Toru,Kamiya Naoto,Kawahara Takashi,Kawakita Mutsushi,Matsubara Nobunaki,Matsumoto Kazumasa,Nishimura Kazuo,Rikiya Taoka,Shimizu Nobuaki,Tagaki Toshio,Kang Taek Won,Kim Jwa Hoon,Kim SeHyun,Lee Hyo Jin,Lee Yun-Gyoo,Rha Sun Young,Seo Ho Kyung,Los Maartje,Zurawski Bogdan,Cortes Paulo,Faustino Catia,Vau Nuno Sineiro,da Luz Ricardo,Atduev Vagif,Kirtbaya Dmitry,Kopyltsov Evgeny,Lykov Aleksandr,Marat Urmantsev,Orlov Sergey,Penkov Konstantin,Pirmagomedov Albert,Semenov Andrey,Varlamov Sergey,Anguera Georgia,Domenech Montserrat,Girones Regina,Gonzalez del Alba Aranzazu,Milagro Nuria Lainez,Luque Raquel,Ortega Esther Martínez,Mellado Begoña,Méndez Vidal María Jose,Fernandez Esteban Nogales,Valderrama Begoña Perez,Marín Alvaro Pinto,Santander Carmen,Huang Yi-Hsiu,Su Wen-Pin,Wu Hung-Chan,Wu WenJeng,Yu Kai-Jie,Bilici Ahmet,Goker Erdem,Gumus Mahmut,Karaoglu Aziz,Kefeli Umut,Köse Fatih,Ozguroglu Mustafa,Tural Deniz,Turk Haci,Yalcin Suayib,Bondarenko Igor,Khareba Gennadii,Kidik Yana,Lychkovskyy Oleksandr,Sakalo Valerii,Shevnia Serghii,Stakhovskyy Eduard,Bahl Amit,Crabb Simon,Powles Thomas,Sankey Peter,Sarwar Mohammad,Benedetto Pasquale,Burgess Earle,Dawson Nancy,Doshi Gurjyot,Fleming Mark,Maly Joseph,Parikh Mamta,Waterhouse David

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3